<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35691950</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-232X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of human genetics</Title><ISOAbbreviation>J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>152</EndPage><MedlinePgn>131-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s10038-022-01055-8</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an intractable disease that causes respiratory failure leading to mortality. The main locus of ALS is motor neurons. The success of antisense oligonucleotide (ASO) therapy in spinal muscular atrophy (SMA), a motor neuron disease, has triggered a paradigm shift in developing ALS therapies. The causative genes of ALS and disease-modifying genes, including those of sporadic ALS, have been identified one after another. Thus, the freedom of target choice for gene therapy has expanded by ASO strategy, leading to new avenues for therapeutic development. Tofersen for superoxide dismutase 1 (SOD1) was a pioneer in developing ASO for ALS. Improving protocols and devising early interventions for the disease are vital. In this review, we updated the knowledge of causative genes in ALS. We summarized the genetic mutations identified in familial ALS and their clinical features, focusing on SOD1, fused in sarcoma (FUS), and transacting response DNA-binding protein. The frequency of the C9ORF72 mutation is low in Japan, unlike in Europe and the United States, while SOD1 and FUS are more common, indicating that the target mutations for gene therapy vary by ethnicity. A genome-wide association study has revealed disease-modifying genes, which could be the novel target of gene therapy. The current status and prospects of gene therapy development were discussed, including ethical issues. Furthermore, we discussed the potential of axonal pathology as new therapeutic targets of ALS from the perspective of early intervention, including intra-axonal transcription factors, neuromuscular junction disconnection, dysregulated local translation, abnormal protein degradation, mitochondrial pathology, impaired axonal transport, aberrant cytoskeleton, and axon branching. We simultaneously discuss important pathological states of cell bodies: persistent stress granules, disrupted nucleocytoplasmic transport, and cryptic splicing. The development of gene therapy based on the elucidation of disease-modifying genes and early intervention in molecular pathology is expected to become an important therapeutic strategy in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8880-8554</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan. naoki@med.tohoku.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warita</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7934-3863</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan. aokim@med.tohoku.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21bm0804003h0003</GrantID><Agency>Japan Agency for Medical Research and Development (AMED)</Agency><Country/></Grant><Grant><GrantID>20H03586</GrantID><Agency>Ministry of Education, Culture, Sports, Science and Technology (MEXT)</Agency><Country/></Grant><Grant><GrantID>21K07411</GrantID><Agency>Ministry of Education, Culture, Sports, Science and Technology (MEXT)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Hum Genet</MedlineTA><NlmUniqueID>9808008</NlmUniqueID><ISSNLinking>1434-5161</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>12</Day><Hour>23</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35691950</ArticleId><ArticleId IdType="pmc">PMC9968660</ArticleId><ArticleId IdType="doi">10.1038/s10038-022-01055-8</ArticleId><ArticleId IdType="pii">10.1038/s10038-022-01055-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96&#x2013;104. doi: 10.1038/nrneurol.2016.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson SB, Downie JM, Tsetsou S, Feusier JE, Figueroa KP, Bromberg MB, et al. The evolving genetic risk for sporadic ALS. Neurology. 2017;89:226&#x2013;33.. doi: 10.1212/WNL.0000000000004109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004109</ArticleId><ArticleId IdType="pmc">PMC5513819</ArticleId><ArticleId IdType="pubmed">28642336</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh NN, Howell MD, Androphy EJ, Singh RN. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 2017;24:520&#x2013;6.. doi: 10.1038/gt.2017.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2017.34</ArticleId><ArticleId IdType="pmc">PMC5623086</ArticleId><ArticleId IdType="pubmed">28485722</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723&#x2013;32.. doi: 10.1056/NEJMoa1702752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625&#x2013;35.. doi: 10.1056/NEJMoa1710504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;19.. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. ALS antisense drug falters in phase III. Nat Rev Drug Disco. 2021;20:883&#x2013;5.. doi: 10.1038/d41573-021-00181-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00181-w</ArticleId><ArticleId IdType="pubmed">34716445</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Ogasawara M, Matsubara Y, Narisawa K, Nakamura S, Itoyama Y, et al. Mild ALS in Japan associated with novel SOD mutation. Nat Genet. 1993;5:323&#x2013;4. doi: 10.1038/ng1293-323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1293-323</ArticleId><ArticleId IdType="pubmed">8298637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993;261:1047&#x2013;51. doi: 10.1126/science.8351519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr., Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;8. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;11.. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;4. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;72. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 2001;29:166&#x2013;73. doi: 10.1038/ng1001-166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-166</ArticleId><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;6. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, Das S, Saberi S, Li Y, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;8. doi: 10.1126/science.aaf6803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, Otomo A, Kunita R, Suzuki-Utsunomiya K, Akatsuka A, Koike M, et al. Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking. PLos ONE. 2010;5:e9805. doi: 10.1371/journal.pone.0009805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009805</ArticleId><ArticleId IdType="pmc">PMC2842444</ArticleId><ArticleId IdType="pubmed">20339559</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;56. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;68. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker AM, Seelen M, van Doormaal PT, van Rheenen W, Bothof RJ, van Riessen T, et al. Large-scale screening in sporadic amyotrophic lateral sclerosis identifies genetic modifiers in C9orf72 repeat carriers. Neurobiol Aging. 2016;39:e9&#x2013;15.. doi: 10.1016/j.neurobiolaging.2015.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.12.012</ArticleId><ArticleId IdType="pubmed">26777436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34:404&#x2013;23.. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Le, Masson G. Genetics of amyotrophic lateral sclerosis: a review. J Neurological Sci. 2019;399:217&#x2013;26.. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Sone J, Atsuta N, Tohnai G, Watanabe H, Yokoi D, et al. Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiol Aging. 2016;39:e1&#x2013;8. doi: 10.1016/j.neurobiolaging.2015.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.11.030</ArticleId><ArticleId IdType="pubmed">26742954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, Niihori T, Warita H, Izumi R, Akiyama T, Kato M, et al. Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol Aging. 2017;53:e1&#x2013;8. doi: 10.1016/j.neurobiolaging.2017.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.01.004</ArticleId><ArticleId IdType="pubmed">28160950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:540&#x2013;9.. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, et al. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosur Psychiatry. 2016;87:821&#x2013;30. doi: 10.1136/jnnp-2015-312751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312751</ArticleId><ArticleId IdType="pubmed">27093948</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Abe K, Itoyama Y. Molecular analyses of the Cu/Zn superoxide dismutase gene in patients with familial amyotrophic lateral sclerosis (ALS) in Japan. Cell Mol Neurobiol. 1998;18:639&#x2013;47. doi: 10.1023/A:1020681802277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1020681802277</ArticleId><ArticleId IdType="pubmed">9876871</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Abe K, Houi K, Ogasawara M, Matsubara Y, Kobayashi T, et al. Variance of age at onset in a Japanese family with amyotrophic lateral sclerosis associated with a novel Cu/Zn superoxide dismutase mutation. Ann Neurol. 1995;37:676&#x2013;9. doi: 10.1002/ana.410370518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410370518</ArticleId><ArticleId IdType="pubmed">7755363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard E, Pegat A, Svahn J, Bouhour F, Leblanc P, Millecamps S, et al. Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS Center Study. Int J Mol Sci. 2020;21:6807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554847</ArticleId><ArticleId IdType="pubmed">32948071</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M, Yang Y, Deng HX, Hung WY, Siddique N, Dellefave L, et al. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72:1634&#x2013;9. doi: 10.1212/01.wnl.0000343509.76828.2a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343509.76828.2a</ArticleId><ArticleId IdType="pmc">PMC2683645</ArticleId><ArticleId IdType="pubmed">19176896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Liu MS, Li XG, Cui LY. H46R SOD1 mutation is consistently associated with a relatively benign form of amyotrophic lateral sclerosis with slow progression. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:610&#x2013;3.. doi: 10.1080/21678421.2016.1199698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1199698</ArticleId><ArticleId IdType="pubmed">27348463</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Ogasawara M, Matsubara Y, Narisawa K, Nakamura S, Itoyama Y, et al. Familial amyotrophic lateral sclerosis (ALS) in Japan associated with H46R mutation in Cu/Zn superoxide dismutase gene: a possible new subtype of familial ALS. J Neurol Sci. 1994;126:77&#x2013;83. doi: 10.1016/0022-510X(94)90097-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90097-3</ArticleId><ArticleId IdType="pubmed">7836951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Aoki M, Ohta M, Nagai M, Ishizaki F, Nakamura S, et al. Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial amyotrophic lateral sclerosis with the homozygous mutation. Neurosci Lett. 2001;312:165&#x2013;8. doi: 10.1016/S0304-3940(01)02212-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02212-1</ArticleId><ArticleId IdType="pubmed">11602336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideshima M, Beck G, Yamadera M, Motoyama Y, Ikenaka K, Kakuda K, et al. A clinicopathological study of ALS with L126S mutation in the SOD1 gene presenting with isolated inferior olivary hypertrophy. Neuropathology. 2020;40:191&#x2013;5.. doi: 10.1111/neup.12620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12620</ArticleId><ArticleId IdType="pubmed">31863610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, Warita H, Takahashi T, Suzuki N, Nishiyama S, Tano O, et al. Prominent sensory involvement in a case of familial amyotrophic lateral sclerosis carrying the L8V SOD1 mutation. Clin Neurol Neurosurg. 2016;150:194&#x2013;6.. doi: 10.1016/j.clineuro.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2016.08.008</ArticleId><ArticleId IdType="pubmed">27543311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88:99&#x2013;105. doi: 10.1136/jnnp-2016-313521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313521</ArticleId><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdynski M, Miszta P, Safranow K, Andersen PM, Morita M, Filipek S, et al. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci Rep. 2022;12:103. doi: 10.1038/s41598-021-03891-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-03891-8</ArticleId><ArticleId IdType="pmc">PMC8742055</ArticleId><ArticleId IdType="pubmed">34996976</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira GRC, Vieira BAA, De Mesquita JF. Comprehensive in silico analysis and molecular dynamics of the superoxide dismutase 1 (SOD1) variants related to amyotrophic lateral sclerosis. PLos ONE. 2021;16:e0247841. doi: 10.1371/journal.pone.0247841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247841</ArticleId><ArticleId IdType="pmc">PMC7906464</ArticleId><ArticleId IdType="pubmed">33630959</ArticleId></ArticleIdList></Reference><Reference><Citation>Radunovic A, Leigh PN. Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry. 1996;61:565&#x2013;72. doi: 10.1136/jnnp.61.6.565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.61.6.565</ArticleId><ArticleId IdType="pmc">PMC486646</ArticleId><ArticleId IdType="pubmed">8971099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH., Jr Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol. 1998;43:703&#x2013;10. doi: 10.1002/ana.410430604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430604</ArticleId><ArticleId IdType="pubmed">9629839</ArticleId></ArticleIdList></Reference><Reference><Citation>den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564&#x2013;9. doi: 10.1002/humu.22981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22981</ArticleId><ArticleId IdType="pubmed">26931183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A, Just W, Rosenbohm A, Muller K, Marroquin N, Goebel I, et al. De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. Neurobiol Aging. 2015;36:3117. e1&#x2013;17.e6. doi: 10.1016/j.neurobiolaging.2015.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.005</ArticleId><ArticleId IdType="pubmed">26362943</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Aoki M, Warita H, Kato M, Mizuno H, Shimakura N, et al. FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. J Hum Genet. 2015;55:252&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20224596</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama T, Warita H, Kato M, Nishiyama A, Izumi R, Ikeda C, et al. Genotype-phenotype relationships in familial amyotrophic lateral sclerosis with FUS/TLS mutations in Japan. Muscle Nerve. 2016;54:398&#x2013;404. doi: 10.1002/mus.25061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25061</ArticleId><ArticleId IdType="pubmed">26823199</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Kato S, Kato M, Warita H, Mizuno H, Kato M, et al. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation. J Neuropathol Exp Neurol. 2015;71:779&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">22878663</ArticleId></ArticleIdList></Reference><Reference><Citation>Eura N, Sugie K, Suzuki N, Kiriyama T, Izumi T, Shimakura N, et al. A juvenile sporadic amyotrophic lateral sclerosis case with P525L mutation in the FUS gene: a rare co-occurrence of autism spectrum disorder and tremor. J Neurol Sci. 2019;398:67&#x2013;8. doi: 10.1016/j.jns.2019.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.032</ArticleId><ArticleId IdType="pubmed">30684766</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;11. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuzawa S, Akiyama T, Nishiyama A, Suzuki N, Kato M, Warita H, et al. TARDBP p.G376D mutation, found in rapid progressive familial ALS, induces mislocalization of TDP-43. eNeurologicalSci. 2018;11:20&#x2013;2. doi: 10.1016/j.ensci.2018.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.04.001</ArticleId><ArticleId IdType="pmc">PMC6006914</ArticleId><ArticleId IdType="pubmed">29928714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4:e1000193. doi: 10.1371/journal.pgen.1000193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000193</ArticleId><ArticleId IdType="pmc">PMC2527686</ArticleId><ArticleId IdType="pubmed">18802454</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms MB, Baloh RH. Clinical neurogenetics: amyotrophic lateral sclerosis. Neurol Clin. 2013;31:929&#x2013;50. doi: 10.1016/j.ncl.2013.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2013.05.003</ArticleId><ArticleId IdType="pmc">PMC3815699</ArticleId><ArticleId IdType="pubmed">24176417</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78:1519&#x2013;26.. doi: 10.1212/WNL.0b013e3182553c88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553c88</ArticleId><ArticleId IdType="pubmed">22539580</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, Johnson L, et al. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet. 2013;21:102&#x2013;8. doi: 10.1038/ejhg.2012.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2012.98</ArticleId><ArticleId IdType="pmc">PMC3522204</ArticleId><ArticleId IdType="pubmed">22692064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A, Marroquin N, Schmoll B, Vielhaber S, Just M, Mayer B, et al. Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiol Aging. 2014;35:1214.e1&#x2013;6. doi: 10.1016/j.neurobiolaging.2013.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.034</ArticleId><ArticleId IdType="pubmed">24378086</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk AE, Weishaupt JH, Andersen PM, Ludolph AC, Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30:252&#x2013;8..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno T, Shiga A, Tsujino A, Sugai A, Kato T, Kanai K, et al. Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. J Neurol Neurosurg Psychiatry. 2013;84:398&#x2013;401. doi: 10.1136/jnnp-2012-302272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302272</ArticleId><ArticleId IdType="pubmed">23012445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogaki K, Li Y, Atsuta N, Tomiyama H, Funayama M, Watanabe H, et al. Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:e11&#x2013;6. doi: 10.1016/j.neurobiolaging.2012.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.05.011</ArticleId><ArticleId IdType="pubmed">22727276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiura H, Takahashi Y, Mitsui J, Yoshida S, Kihira T, Kokubo Y, et al. C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Arch Neurol. 2012;69:1154&#x2013;8. doi: 10.1001/archneurol.2012.1219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.1219</ArticleId><ArticleId IdType="pubmed">22637429</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Maroof AM, Merkle FT, Koszka K, Intoh A, Armstrong I, et al. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat Neurosci. 2013;16:1725&#x2013;7. doi: 10.1038/nn.3566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3566</ArticleId><ArticleId IdType="pmc">PMC4397902</ArticleId><ArticleId IdType="pubmed">24185425</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8:347ra93. doi: 10.1126/scitranslmed.aaf6038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature. 2020;582:89&#x2013;94. doi: 10.1038/s41586-020-2288-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2288-7</ArticleId><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="pubmed">32483373</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, Taylor JP. Pathological phase transitions in ALS-FTD impair dynamic RNA-protein granules. RNA. 2022;28:97&#x2013;113. doi: 10.1261/rna.079001.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.079001.121</ArticleId><ArticleId IdType="pmc">PMC8675280</ArticleId><ArticleId IdType="pubmed">34706979</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C, Herranz-Martin S, Karyka E, Liao C, Lewis K, Elsayed W, et al. C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat Neurosci. 2017;20:1225&#x2013;35.. doi: 10.1038/nn.4604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4604</ArticleId><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci USA. 2017;114:E1111&#x2013;7.. doi: 10.1073/pnas.1620293114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1620293114</ArticleId><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;9.. doi: 10.1038/nn.4085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4085</ArticleId><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue GM, Castelli LM, Ferraiuolo L, Sanchez-Martinez A, Cooper-Knock J, Higginbottom A, et al. SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nat Commun. 2017;8:16063. doi: 10.1038/ncomms16063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms16063</ArticleId><ArticleId IdType="pmc">PMC5504286</ArticleId><ArticleId IdType="pubmed">28677678</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaai7866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab. 2001;74:458&#x2013;75.. doi: 10.1006/mgme.2001.3256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mgme.2001.3256</ArticleId><ArticleId IdType="pmc">PMC6277059</ArticleId><ArticleId IdType="pubmed">11749051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimonis V. Inclusion body myopathy with paget disease of bone and/or frontotemporal dementia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews&#xae;. Seattle (WA): University of Washington, Seattle; 1993&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">20301649</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP. Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology. 2015;85:658&#x2013;60.. doi: 10.1212/WNL.0000000000001862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001862</ArticleId><ArticleId IdType="pubmed">26208960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;73. doi: 10.1038/nature11922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11922</ArticleId><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Fernandez C, Weihl CC, Katzen H, Steele J, et al. Motor neuron involvement in multisystem proteinopathy: implications for ALS. Neurology. 2013;80:1874&#x2013;80.. doi: 10.1212/WNL.0b013e3182929fc3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182929fc3</ArticleId><ArticleId IdType="pmc">PMC3908355</ArticleId><ArticleId IdType="pubmed">23635965</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem J. 2017;474:1417&#x2013;38.. doi: 10.1042/BCJ20160499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160499</ArticleId><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumi R, Warita H, Niihori T, Takahashi T, Tateyama M, Suzuki N, et al. Isolated inclusion body myopathy caused by a multisystem proteinopathy-linked hnRNPA1 mutation. Neurol Genet. 2015;1:e23. doi: 10.1212/NXG.0000000000000023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000023</ArticleId><ArticleId IdType="pmc">PMC4809462</ArticleId><ArticleId IdType="pubmed">27066560</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Aoki M, Mizuno H, Onodera Y, Takahashi T, Nagata T, et al. Late-onset distal myopathy with rimmed vacuoles without mutation in the GNE or dysferlin genes. Muscle Nerve. 2005;32:812&#x2013;4. doi: 10.1002/mus.20417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20417</ArticleId><ArticleId IdType="pubmed">16116644</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich KA, Roggenbuck J, Kolb SJ. Searching far and genome-wide: the relevance of association studies in amyotrophic lateral sclerosis. Front Neurosci. 2020;14:603023. doi: 10.3389/fnins.2020.603023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.603023</ArticleId><ArticleId IdType="pmc">PMC7873947</ArticleId><ArticleId IdType="pubmed">33584177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med. 2007;357:775&#x2013;88. doi: 10.1056/NEJMoa070174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa070174</ArticleId><ArticleId IdType="pubmed">17671248</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Van Vught PW, Blauw HM, Franke L, Saris CG, Andersen PM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol. 2007;6:869&#x2013;77. doi: 10.1016/S1474-4422(07)70222-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70222-3</ArticleId><ArticleId IdType="pubmed">17827064</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, Van den Bosch L, et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2008;40:29&#x2013;31. doi: 10.1038/ng.2007.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2007.52</ArticleId><ArticleId IdType="pubmed">18084291</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;7. doi: 10.1038/ng.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2009;106:9004&#x2013;9. doi: 10.1073/pnas.0812937106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812937106</ArticleId><ArticleId IdType="pmc">PMC2683883</ArticleId><ArticleId IdType="pubmed">19451621</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, Saris CG, van Rheenen W, Franke L, Jansen RC, van Es MA, et al. Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. PLos ONE. 2012;7:e35333. doi: 10.1371/journal.pone.0035333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035333</ArticleId><ArticleId IdType="pmc">PMC3324559</ArticleId><ArticleId IdType="pubmed">22509407</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida A, Takahashi A, Kubo M, Saito S, Hosono N, Ohnishi Y, et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum Mol Genet. 2011;20:3684&#x2013;92. doi: 10.1093/hmg/ddr268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr268</ArticleId><ArticleId IdType="pubmed">21665992</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng M, Wei L, Zuo X, Tian Y, Xie F, Hu P, et al. Genome-wide association analyses in Han Chinese identify two new susceptibility loci for amyotrophic lateral sclerosis. Nat Genet. 2013;45:697&#x2013;700. doi: 10.1038/ng.2627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2627</ArticleId><ArticleId IdType="pubmed">23624525</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, Ratti A, Gellera C, Lin K, Tiloca C, Moskvina V, et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23:2220&#x2013;31. doi: 10.1093/hmg/ddt587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt587</ArticleId><ArticleId IdType="pmc">PMC3959809</ArticleId><ArticleId IdType="pubmed">24256812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;41. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohnai G, Nakamura R, Sone J, Nakatochi M, Yokoi D, Katsuno M, et al. Frequency and characteristics of the TBK1 gene variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2018;64:158.e15&#x2013;58e19. doi: 10.1016/j.neurobiolaging.2017.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.12.005</ArticleId><ArticleId IdType="pubmed">29398122</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Misawa K, Tohnai G, Nakatochi M, Furuhashi S, Atsuta N, et al. A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun Biol. 2020;3:526. doi: 10.1038/s42003-020-01251-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01251-2</ArticleId><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Lin T, Al Khleifat A, Jones AR, Opie-Martin S, Coleman JRI, et al. Genome-wide meta-analysis finds the ACSL5-ZDHHC6 locus is associated with ALS and links weight loss to the disease genetics. Cell Rep. 2020;33:108323. doi: 10.1016/j.celrep.2020.108323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108323</ArticleId><ArticleId IdType="pmc">PMC7610013</ArticleId><ArticleId IdType="pubmed">33113361</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Chia R, Miller DE, Li R, Kumaran R, Abramzon Y, et al. Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurol. 2021;78:1236&#x2013;48. doi: 10.1001/jamaneurol.2021.2598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2598</ArticleId><ArticleId IdType="pmc">PMC8406220</ArticleId><ArticleId IdType="pubmed">34459874</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, van Vugt J, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53:1636&#x2013;48. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, Boddy S, Islam M, Kurz J, Whittaker KJ, Moll T, et al. A review of Mendelian randomization in amyotrophic lateral sclerosis. Brain. 2021;145:832&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050546</ArticleId><ArticleId IdType="pubmed">34791088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Cooper-Knock J, Weimer AK, Shi M, Moll T, Marshall JNG, et al. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron. 2022;110;992&#x2013;1008.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017397</ArticleId><ArticleId IdType="pubmed">35045337</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CGJ, Blauw HM, van Vught PWJ, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;7.. doi: 10.1038/ng.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyamin B, He J, Zhao QY, Gratten J, Garton F, Leo PJ, et al. Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. Nat. Commun. 2017;8:611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5606989</ArticleId><ArticleId IdType="pubmed">28931804</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Misawa K, Tohnai G, Nakatochi M, Furuhashi S, Atsuta N, et al. A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun. Biol. 2020;3:526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, van Vugt JJFA, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53:1636. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HHG, Westeneng HJ, van der Burgh HK, van Es MA, Bakker LA, van Veenhuijzen K, et al. The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis. Ann Neurol. 2020;88:796&#x2013;806. doi: 10.1002/ana.25841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25841</ArticleId><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603:124&#x2013;30.. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;7.. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho M, Quade B, Trimbuch T, Xu J, Sari L, Rizo J, et al. Control of neurotransmitter release by two distinct membrane-binding faces of the Munc13-1 C1C2B region. Elife. 2021;10:e72030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648301</ArticleId><ArticleId IdType="pubmed">34779770</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoccaro MP, Bartoletti-Stella A, Piras S, Pession A, De Massis P, Oppi F, et al. Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature. J Neurol. 2017;264:1426&#x2013;33.. doi: 10.1007/s00415-017-8540-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8540-x</ArticleId><ArticleId IdType="pubmed">28620717</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Khleifat A, Iacoangeli A, van Vugt J, Bowles H, Moisse M, Zwamborn RAJ, et al. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. NPJ Genom Med. 2022;7:8. doi: 10.1038/s41525-021-00267-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-021-00267-9</ArticleId><ArticleId IdType="pmc">PMC8799638</ArticleId><ArticleId IdType="pubmed">35091648</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, Thompson T, Li J, Kaye JA, Lim RG, Wu J, et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat Neurosci. 2022;25:226&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller TM, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015;77:100&#x2013;13. doi: 10.1002/ana.24306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24306</ArticleId><ArticleId IdType="pmc">PMC4293318</ArticleId><ArticleId IdType="pubmed">25382069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang SY, Hsu JS, Teo KC, Li Y, Kung MHW, Cheah KSE, et al. Burden of rare variants in ALS genes influences survival in familial and sporadic ALS. Neurobiol Aging. 2017;58:238.e9&#x2013;15.. doi: 10.1016/j.neurobiolaging.2017.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.06.007</ArticleId><ArticleId IdType="pubmed">28709720</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse H, Ishiura H, Mitsui J, Takahashi Y, Matsukawa T, Tanaka M, et al. Burden of rare variants in causative genes for amyotrophic lateral sclerosis (ALS) accelerates age at onset of ALS. J Neurol Neurosurg Psychiatry. 2019;90:537&#x2013;42.. doi: 10.1136/jnnp-2018-318568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318568</ArticleId><ArticleId IdType="pubmed">30355605</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;75. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart MP, Gitler AD. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci. 2012;32:9133&#x2013;42. doi: 10.1523/JNEUROSCI.0996-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0996-12.2012</ArticleId><ArticleId IdType="pmc">PMC3418890</ArticleId><ArticleId IdType="pubmed">22764223</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse H, Matsukawa T, Ishiura H, Mitsui J, Takahashi Y, Takano H, et al. Association of ATXN2 intermediate-length CAG repeats with amyotrophic lateral sclerosis correlates with the distributions of normal CAG repeat alleles among individual ethnic populations. Neurogenetics. 2019;20:65&#x2013;71. doi: 10.1007/s10048-019-00570-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-019-00570-9</ArticleId><ArticleId IdType="pubmed">30847648</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R.Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone B, Conforti FL. Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: how common are common mutations in ALS genes? Expert Rev Mol Diagn. 2020;20:703&#x2013;14.. doi: 10.1080/14737159.2020.1779060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2020.1779060</ArticleId><ArticleId IdType="pubmed">32497448</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Parker MD, Cooper-Knock J, Verber NS, Tuddenham L, Heath P, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosur Psychiatry. 2021;92:510&#x2013;8.. doi: 10.1136/jnnp-2020-325014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology. 2021;55:342&#x2013;53.. doi: 10.1159/000516752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516752</ArticleId><ArticleId IdType="pubmed">34247168</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603&#x2013;15. doi: 10.1038/nrneurol.2011.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassano M, Calvo A, Moglia C, Brunetti M, Barberis M, Sbaiz L, et al. Mutational analysis of known ALS genes in an Italian population-based cohort. Neurology. 2021;96:E600&#x2013;9.. doi: 10.1212/WNL.0000000000011209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011209</ArticleId><ArticleId IdType="pmc">PMC7905787</ArticleId><ArticleId IdType="pubmed">33208543</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Canosa A, Brunetti M, Barberis M, Traynor BJ, et al. A de novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. Neurobiol Aging. 2014;35:1513.e7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961545</ArticleId><ArticleId IdType="pubmed">24439481</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A, Just W, Rosenbohm A, Muller K, Marroquin N, Goebel I, et al. De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. Neurobiol Aging. 2015;36:3117.e1&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26362943</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffita-Mesa JM, Pupo JMR, Sera RM, Mojena YV, Kouri V, Laguna-Salvia L, et al. De novo mutations in ataxin-2 gene and ALS risk. PLos ONE. 2013;8:e70560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735591</ArticleId><ArticleId IdType="pubmed">23936447</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013;93:900&#x2013;5.. doi: 10.1016/j.ajhg.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.09.008</ArticleId><ArticleId IdType="pmc">PMC3824132</ArticleId><ArticleId IdType="pubmed">24119685</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo K, Lim SM, Nahm M, Kim YE, Oh KW, Park HT, et al. A de novo RAPGEF2 variant identified in a sporadic amyotrophic lateral sclerosis patient impairs microtubule stability and axonal mitochondria distribution. Exp Neurobiol. 2018;27:550&#x2013;63.. doi: 10.5607/en.2018.27.6.550.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2018.27.6.550</ArticleId><ArticleId IdType="pmc">PMC6318558</ArticleId><ArticleId IdType="pubmed">30636905</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 2022;145:1207&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129091</ArticleId><ArticleId IdType="pubmed">35020823</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams D, Gonzalez-Duarte A, O&#x2019;Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11&#x2013;21. doi: 10.1056/NEJMoa1716153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716153</ArticleId><ArticleId IdType="pubmed">29972753</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29:3345&#x2013;58.. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Le Masson G. RNA-targeted therapies and amyotrophic lateral sclerosis. Biomedicines. 2018;6:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5874666</ArticleId><ArticleId IdType="pubmed">29342921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31:648&#x2013;54.. doi: 10.1097/WCO.0000000000000594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000594</ArticleId><ArticleId IdType="pmc">PMC7291817</ArticleId><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;50. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, Moazami MP, Yang H, McKenna-Yasek D, Douthwright CL, Pinto C, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2021;28:117&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28:104&#x2013;16.. doi: 10.1038/s41591-021-01615-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;79.. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennemark P, Walter K, Clemmensen N, Rekic D, Nilsson CAM, Knochel J, et al. An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med. 2021;13:eabe9117.</Citation><ArticleIdList><ArticleId IdType="pubmed">33980578</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T, Dwyer CA, Yoshida-Tanaka K, Ihara K, Ohyagi M, Kaburagi H, et al. Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. Nat Biotechnol. 2021;39:1529&#x2013;36.. doi: 10.1038/s41587-021-00972-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00972-x</ArticleId><ArticleId IdType="pubmed">34385691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29:464&#x2013;88.. doi: 10.1016/j.ymthe.2020.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7854298</ArticleId><ArticleId IdType="pubmed">33309881</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. 2009;17:1187&#x2013;96. doi: 10.1038/mt.2009.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.71</ArticleId><ArticleId IdType="pmc">PMC2835208</ArticleId><ArticleId IdType="pubmed">19367261</ArticleId></ArticleIdList></Reference><Reference><Citation>Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284&#x2013;93.. doi: 10.1016/S1474-4422(21)00001-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00001-6</ArticleId><ArticleId IdType="pubmed">33743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HN, Tjostheim S, Dasilva K, Taylor D, Zhao B, Rakhit R, et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J Neurosci. 2012;32:8791&#x2013;9. doi: 10.1523/JNEUROSCI.5053-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5053-11.2012</ArticleId><ArticleId IdType="pmc">PMC6622344</ArticleId><ArticleId IdType="pubmed">22745481</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y, Shodai A, Morimura T, Hikiami R, Minamiyama S, Ayaki T, et al. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. Sci Rep. 2018;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902603</ArticleId><ArticleId IdType="pubmed">29662239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush JA, Aikawa H, Fuerst R, Li Y, Ursu A, Meyer SM, et al. Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(G(4)C(2)) repeat expansion in vitro and in vivo ALS models. Sci Transl Med. 2021;13:eabd5991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9533739</ArticleId><ArticleId IdType="pubmed">34705518</ArticleId></ArticleIdList></Reference><Reference><Citation>Diller DJ, Swanson J, Bayden AS, Jarosinski M, Audie J. Rational, computer-enabled peptide drug design: principles, methods, applications and future directions. Future Med Chem. 2015;7:2173&#x2013;93. doi: 10.4155/fmc.15.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.15.142</ArticleId><ArticleId IdType="pubmed">26510691</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Disco. 2002;1:727&#x2013;30. doi: 10.1038/nrd892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd892</ArticleId><ArticleId IdType="pubmed">12209152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichiyanagi N, Fujimori K, Yano M, Ishihara-Fujisaki C, Sone T, Akiyama T, et al. Establishment of in vitro FUS-associated familial amyotrophic lateral sclerosis model using human induced pluripotent stem cells. Stem Cell Rep. 2016;6:496&#x2013;510. doi: 10.1016/j.stemcr.2016.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.02.011</ArticleId><ArticleId IdType="pmc">PMC4834049</ArticleId><ArticleId IdType="pubmed">26997647</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Morimoto S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell. 2022;29:189&#x2013;208. doi: 10.1016/j.stem.2022.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2022.01.007</ArticleId><ArticleId IdType="pubmed">35120619</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaaf3962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med. 2018;24:1579&#x2013;89.. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S, Takahashi S, Ito D, Dat&#xe9; Y, Okada K, Muh Chyi C, et al. Ropinirole hydrochloride for amyotrophic lateral sclerosis: a single-center, randomized feasibility, double-blind, placebo-controlled trial. medRxiv 2021.12.05.21267266; 10.1101/2021.12.05.21267266 [Preprint]. 2021.</Citation></Reference><Reference><Citation>Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78:186&#x2013;96. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, Kasai N, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci. 2001;21:9246&#x2013;54.. doi: 10.1523/JNEUROSCI.21-23-09246.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-23-09246.2001</ArticleId><ArticleId IdType="pmc">PMC6763929</ArticleId><ArticleId IdType="pubmed">11717358</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440&#x2013;3. doi: 10.1038/342440a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/342440a0</ArticleId><ArticleId IdType="pubmed">2531289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci. 2002;22:6537&#x2013;48. doi: 10.1523/JNEUROSCI.22-15-06537.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-15-06537.2002</ArticleId><ArticleId IdType="pmc">PMC6758174</ArticleId><ArticleId IdType="pubmed">12151533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki A, Aoki M, Nagai M, Warita H, Kato S, Kato M, et al. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol. 2007;66:1037&#x2013;44. doi: 10.1097/nen.0b013e318159886b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e318159886b</ArticleId><ArticleId IdType="pubmed">17984685</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852&#x2013;6. doi: 10.1212/01.wnl.0000203120.85850.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, O&#x2019;Reilly EJ, Molsberry S, Kolonel LN, Le Marchand L, Paganoni S, et al. Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575132</ArticleId><ArticleId IdType="pubmed">34380747</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl J Med. 2020;383:919&#x2013;30.. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I, Yacovzada NS, Yanowski E, Coenen-Stass A, Grosskreutz J, Lu CH, et al. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat Neurosci. 2021;24:1534&#x2013;41.. doi: 10.1038/s41593-021-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Manberg A, Skene N, Sanders F, Trusohamn M, Remnestal J, Szczepinska A, et al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat Med. 2021;27:640&#x2013;6.. doi: 10.1038/s41591-021-01295-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162&#x2013;8. doi: 10.3109/21678421.2012.762930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.762930</ArticleId><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:406&#x2013;13.. doi: 10.3109/21678421.2014.943672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.943672</ArticleId><ArticleId IdType="pubmed">25125035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, et al. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021;20:821&#x2013;31.. doi: 10.1016/S1474-4422(21)00242-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00242-8</ArticleId><ArticleId IdType="pubmed">34536404</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S, Takahashi S, Fukushima K, Saya H, Suzuki N, Aoki M, et al. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial) Regen Ther. 2019;11:143&#x2013;66.. doi: 10.1016/j.reth.2019.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reth.2019.07.002</ArticleId><ArticleId IdType="pmc">PMC6661418</ArticleId><ArticleId IdType="pubmed">31384636</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, van den Berg LH, Lu Y. Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF). J Neurol Neurosurg Psychiatry. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016230</ArticleId><ArticleId IdType="pubmed">34921121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3:fcab242. doi: 10.1093/braincomms/fcab242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab242</ArticleId><ArticleId IdType="pmc">PMC8659356</ArticleId><ArticleId IdType="pubmed">34901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller K, Oh KW, Nordin A, Panthi S, Kim SH, Nordin F, et al. De novo mutations in SOD1 are a cause of ALS. J Neurol Neurosur Ps. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784989</ArticleId><ArticleId IdType="pubmed">34518333</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian F, Yang W, Mordes DA, Wang JY, Salameh JS, Mok J, et al. Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging. Nat Commun. 2016;7:13283. doi: 10.1038/ncomms13283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13283</ArticleId><ArticleId IdType="pmc">PMC5095598</ArticleId><ArticleId IdType="pubmed">27796305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232&#x2013;40. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Ticozzi N, Fallini C, Gkazi AS, Topp S, Kenna KP, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84:324&#x2013;31. doi: 10.1016/j.neuron.2014.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.09.027</ArticleId><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheway G, Schmidts M, Mans DA, Szymanska K, Nguyen TT, Racher H, et al. An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes. Nat Cell Biol. 2015;17:1074&#x2013;87.. doi: 10.1038/ncb3201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3201</ArticleId><ArticleId IdType="pmc">PMC4536769</ArticleId><ArticleId IdType="pubmed">26167768</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Y, Nakagawa T, Akiyama T, Nakagawa M, Suzuki N, Warita H, et al. An Amyotrophic Lateral Sclerosis-Associated Mutant of C21ORF2 Is Stabilized by NEK1-Mediated Hyperphosphorylation and the Inability to Bind FBXO3. iScience. 2020;23:101491. doi: 10.1016/j.isci.2020.101491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101491</ArticleId><ArticleId IdType="pmc">PMC7481237</ArticleId><ArticleId IdType="pubmed">32891887</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese M, Saal L, Appenzeller S, Moradi M, Baluapuri A, Sendtner M. Whole transcriptome profiling reveals the RNA content of motor axons. Nucleic Acids Res. 2016;44:e33. doi: 10.1093/nar/gkv1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1027</ArticleId><ArticleId IdType="pmc">PMC4770199</ArticleId><ArticleId IdType="pubmed">26464439</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotem N, Magen I, Ionescu A, Gershoni-Emek N, Altman T, Costa CJ, et al. ALS Along the Axons - Expression of Coding and Noncoding RNA Differs in Axons of ALS models. Sci Rep. 2017;7:44500. doi: 10.1038/srep44500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44500</ArticleId><ArticleId IdType="pmc">PMC5353576</ArticleId><ArticleId IdType="pubmed">28300211</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Akiyama T, Warita H, Aoki M. Omics Approach to Axonal Dysfunction of Motor Neurons in Amyotrophic Lateral Sclerosis (ALS) Front Neurosci. 2020;14:194. doi: 10.3389/fnins.2020.00194.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00194</ArticleId><ArticleId IdType="pmc">PMC7109447</ArticleId><ArticleId IdType="pubmed">32269505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawada J, Kaneda S, Kirihara T, Maroof A, Levi T, Eggan K, et al. Generation of a Motor Nerve Organoid with Human Stem Cell-Derived Neurons. Stem Cell Rep. 2017;9:1441&#x2013;9.. doi: 10.1016/j.stemcr.2017.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.09.021</ArticleId><ArticleId IdType="pmc">PMC5831012</ArticleId><ArticleId IdType="pubmed">29107592</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Yamanaka S. iPS cell technologies: significance and applications to CNS regeneration and disease. Mol Brain. 2014;7:22. doi: 10.1186/1756-6606-7-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-7-22</ArticleId><ArticleId IdType="pmc">PMC3977688</ArticleId><ArticleId IdType="pubmed">24685317</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama T, Suzuki N, Ishikawa M, Fujimori T, Sone K,. Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons. EBioMedicine. 2019;(in press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642224</ArticleId><ArticleId IdType="pubmed">31262712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafragette A, Bardo MT, Lardeux V, Solinas M, Thiriet N. Reduction of Cocaine-Induced Locomotor Effects by Enriched Environment Is Associated with Cell-Specific Accumulation of DeltaFosB in Striatal and Cortical Subregions. Int J Neuropsychopharmacol. 2017;20:237&#x2013;46..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408985</ArticleId><ArticleId IdType="pubmed">27815415</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill ME, Walker DM, Gancarz AM, Wang ZJ, Lardner CK, Bagot RC, et al. The dendritic spine morphogenic effects of repeated cocaine use occur through the regulation of serum response factor signaling. Mol Psychiatry. 2018;23:1474&#x2013;86.. doi: 10.1038/mp.2017.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.116</ArticleId><ArticleId IdType="pmc">PMC5709273</ArticleId><ArticleId IdType="pubmed">28555077</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasiadou S, Knoll B. The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration. Exp Neurol. 2016;279:243&#x2013;60.. doi: 10.1016/j.expneurol.2016.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2016.03.012</ArticleId><ArticleId IdType="pubmed">26980486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhinge A, Namboori SC, Zhang X, VanDongen AMJ, Stanton LW. Genetic correction of SOD1 mutant iPSCs reveals ERK and JNK activated AP1 as a driver of neurodegeneration in amyotrophic lateral sclerosis. Stem Cell Rep. 2017;8:856&#x2013;69.. doi: 10.1016/j.stemcr.2017.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.02.019</ArticleId><ArticleId IdType="pmc">PMC5390134</ArticleId><ArticleId IdType="pubmed">28366453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuzawa S, Suzuki N, Akiyama T, Ishikawa M, Sone T, Kawada J, et al. Reduced PHOX2B stability causes axonal growth impairment in motor neurons with TARDBP mutations. Stem Cell Rep. 2021;16:1527&#x2013;41.. doi: 10.1016/j.stemcr.2021.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.04.021</ArticleId><ArticleId IdType="pmc">PMC8190591</ArticleId><ArticleId IdType="pubmed">34048688</ArticleId></ArticleIdList></Reference><Reference><Citation>Allodi I, Nijssen J, Benitez JA, Schweingruber C, Fuchs A, Bonvicini G, et al. Modeling motor neuron resilience in ALS using stem cells. Stem Cell Rep. 2019;12:1329&#x2013;41.. doi: 10.1016/j.stemcr.2019.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.04.009</ArticleId><ArticleId IdType="pmc">PMC6565614</ArticleId><ArticleId IdType="pubmed">31080111</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Lee JJ, Park NY, Dubey SK, Kim T, Ruan K, et al. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat Neurosci. 2021;24:1673&#x2013;85. doi: 10.1038/s41593-021-00944-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00944-z</ArticleId><ArticleId IdType="pmc">PMC8639773</ArticleId><ArticleId IdType="pubmed">34782793</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias J, Holt CE, Sotelo JR, Sotelo-Silveira JR. Axon microdissection and transcriptome profiling reveals the in vivo RNA content of fully differentiated myelinated motor axons. Rna. 2020;26:595&#x2013;612. doi: 10.1261/rna.073700.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.073700.119</ArticleId><ArticleId IdType="pmc">PMC7161357</ArticleId><ArticleId IdType="pubmed">32051223</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front Neurosci. 2014;8:252. doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkawara B, Ito M, Ohno K. Secreted Signaling Molecules at the Neuromuscular Junction in Physiology and Pathology. Int J Mol Sci. 2021;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7957818</ArticleId><ArticleId IdType="pubmed">33671084</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau E, Di Polo A, Vande Velde C, Robitaille R. Dynamic neuromuscular remodeling precedes motor-unit loss in a mouse model of ALS. Elife. 2018;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234026</ArticleId><ArticleId IdType="pubmed">30320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi S, Tezuka T, Arimura S, Tomono T, Okada T, Yamanashi Y. DOK7 gene therapy enhances motor activity and life span in ALS model mice. EMBO Mol Med. 2017;9:880&#x2013;9.. doi: 10.15252/emmm.201607298.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607298</ArticleId><ArticleId IdType="pmc">PMC5494517</ArticleId><ArticleId IdType="pubmed">28490573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Gao J, Liu J, Siedlak SL, Torres S, Fujioka H, et al. Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles. Cell Metab. 2018;28:400&#x2013;14.e8. doi: 10.1016/j.cmet.2018.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.06.011</ArticleId><ArticleId IdType="pmc">PMC6125186</ArticleId><ArticleId IdType="pubmed">30017354</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, Priesmann D, Gradus-Pery T, Farberov L, et al. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12:6914. doi: 10.1038/s41467-021-27221-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27221-8</ArticleId><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Picchiarelli G, Demestre M, Zuko A, Been M, Higelin J, Dieterle S, et al. FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nat Neurosci. 2019;22:1793&#x2013;805.. doi: 10.1038/s41593-019-0498-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0498-9</ArticleId><ArticleId IdType="pmc">PMC6858880</ArticleId><ArticleId IdType="pubmed">31591561</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoen M, Reichel JM, Demestre M, Putz S, Deshpande D, Proepper C, et al. Super-Resolution Microscopy Reveals Presynaptic Localization of the ALS/FTD Related Protein FUS in Hippocampal Neurons. Front Cell Neurosci. 2015;9:496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709451</ArticleId><ArticleId IdType="pubmed">26834559</ArticleId></ArticleIdList></Reference><Reference><Citation>So E, Mitchell JC, Memmi C, Chennell G, Vizcay-Barrena G, Allison L, et al. Mitochondrial abnormalities and disruption of the neuromuscular junction precede the clinical phenotype and motor neuron loss in hFUSWT transgenic mice. Hum Mol Genet. 2018;27:463&#x2013;74.. doi: 10.1093/hmg/ddx415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx415</ArticleId><ArticleId IdType="pmc">PMC5886082</ArticleId><ArticleId IdType="pubmed">29194538</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong GA, Drapeau P. Loss and gain of FUS function impair neuromuscular synaptic transmission in a genetic model of ALS. Hum Mol Genet. 2013;22:4282&#x2013;92. doi: 10.1093/hmg/ddt278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt278</ArticleId><ArticleId IdType="pubmed">23771027</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, et al. Cell-to-cell transmission of dipeptide repeat proteins linked to C9orf72-ALS/FTD. Cell Rep. 2016;17:645&#x2013;52.. doi: 10.1016/j.celrep.2016.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.09.032</ArticleId><ArticleId IdType="pmc">PMC5078984</ArticleId><ArticleId IdType="pubmed">27732842</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9:4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;34. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011;286:18664&#x2013;72. doi: 10.1074/jbc.M111.231209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.231209</ArticleId><ArticleId IdType="pmc">PMC3099683</ArticleId><ArticleId IdType="pubmed">21454603</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoklund Dittlau K, Krasnow EN, Fumagalli L, Vandoorne T, Baatsen P, Kerstens A, et al. Generation of human motor units with functional neuromuscular junctions in microfluidic devices. J Vis Exp. 2021. 10.3791/62959.</Citation><ArticleIdList><ArticleId IdType="pubmed">34570099</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T, Uzel SGM, Kamm RD. On-chip 3D neuromuscular model for drug screening and precision medicine in neuromuscular disease. Nat Protoc. 2020;15:421&#x2013;49.. doi: 10.1038/s41596-019-0248-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-019-0248-1</ArticleId><ArticleId IdType="pubmed">31932771</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrato G, Nguyen T, Macosko EZ, Sherwood JL, Min Yang S, Berger DR, et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature. 2017;545:48&#x2013;53. doi: 10.1038/nature22047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22047</ArticleId><ArticleId IdType="pmc">PMC5659341</ArticleId><ArticleId IdType="pubmed">28445462</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y, Tanaka Y, Patterson B, Kang YJ, Govindaiah G, Roselaar N, et al. Fusion of regionally specified hPSC-derived organoids models human brain development and interneuron migration. Cell Stem Cell. 2017;21:383&#x2013;98.e7. doi: 10.1016/j.stem.2017.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2017.07.007</ArticleId><ArticleId IdType="pmc">PMC5720381</ArticleId><ArticleId IdType="pubmed">28757360</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaus J, Kanton S, Kyrousi C, Ayo-Martin AC, Di Giaimo R, Riesenberg S, et al. Altered neuronal migratory trajectories in human cerebral organoids derived from individuals with neuronal heterotopia. Nat Med. 2019;25:561&#x2013;68.. doi: 10.1038/s41591-019-0371-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0371-0</ArticleId><ArticleId IdType="pubmed">30858616</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing L, Bassell GJ. mRNA localization: an orchestration of assembly, traffic and synthesis. Traffic. 2013;14:2&#x2013;14. doi: 10.1111/tra.12004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tra.12004</ArticleId><ArticleId IdType="pmc">PMC3548013</ArticleId><ArticleId IdType="pubmed">22913533</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Clarelli F, Domi T, Cerri F, Gallia F, Trimarco A, et al. Unraveling gene expression profiles in peripheral motor nerve from amyotrophic lateral sclerosis patients: insights into pathogenesis. Sci Rep. 2016;6:39297. doi: 10.1038/srep39297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39297</ArticleId><ArticleId IdType="pmc">PMC5159906</ArticleId><ArticleId IdType="pubmed">27982123</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen MH, Peviani M, Hendricusdottir R, Bell EM, Lammens M, Smit AB, et al. Increased axonal ribosome numbers is an early event in the pathogenesis of amyotrophic lateral sclerosis. PLoS ONE. 2014;9:e87255. doi: 10.1371/journal.pone.0087255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087255</ArticleId><ArticleId IdType="pmc">PMC3907527</ArticleId><ArticleId IdType="pubmed">24498056</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano S, Jinno J, Abdelhamid RF, Jin Y, Shibata M, Watanabe S, et al. TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. Acta Neuropathol. 2020;140:695&#x2013;713. doi: 10.1007/s00401-020-02205-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02205-y</ArticleId><ArticleId IdType="pubmed">32803350</ArticleId></ArticleIdList></Reference><Reference><Citation>Rage F, Boulisfane N, Rihan K, Neel H, Gostan T, Bertrand E, et al. Genome-wide identification of mRNAs associated with the protein SMN whose depletion decreases their axonal localization. RNA. 2013;19:1755&#x2013;66. doi: 10.1261/rna.040204.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.040204.113</ArticleId><ArticleId IdType="pmc">PMC3884661</ArticleId><ArticleId IdType="pubmed">24152552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kye MJ, Niederst ED, Wertz MH, Goncalves Ido C, Akten B, Dover KZ, et al. SMN regulates axonal local translation via miR-183/mTOR pathway. Hum Mol Genet. 2014;23:6318&#x2013;31. doi: 10.1093/hmg/ddu350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu350</ArticleId><ArticleId IdType="pmc">PMC4271102</ArticleId><ArticleId IdType="pubmed">25055867</ArticleId></ArticleIdList></Reference><Reference><Citation>Umegaki Y, Brotons AM, Nakanishi Y, Luo Z, Zhang H, Bonni A, et al. Palladin is a neuron-specific translational target of mTOR signaling that regulates axon morphogenesis. J Neurosci. 2018;38:4985&#x2013;95.. doi: 10.1523/JNEUROSCI.2370-17.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2370-17.2018</ArticleId><ArticleId IdType="pmc">PMC5966794</ArticleId><ArticleId IdType="pubmed">29712777</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, Donlin-Asp PG, Rouanet JP, Bassell GJ, Rossoll W. Deficiency of the survival of motor neuron protein impairs mRNA localization and local translation in the growth cone of motor neurons. J Neurosci. 2016;36:3811&#x2013;20. doi: 10.1523/JNEUROSCI.2396-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2396-15.2016</ArticleId><ArticleId IdType="pmc">PMC4812137</ArticleId><ArticleId IdType="pubmed">27030765</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen EJ, Fumoto K, Blokhuis AM, Engelen-Lee J, Zhou Y, van den Heuvel DM, et al. ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN. Hum Mol Genet. 2013;22:3690&#x2013;704. doi: 10.1093/hmg/ddt222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt222</ArticleId><ArticleId IdType="pubmed">23681068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Chen S, Yu Y, Yan B, Haertlein TC, Carrasco MA, et al. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep. 2012;2:799&#x2013;806. doi: 10.1016/j.celrep.2012.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.08.025</ArticleId><ArticleId IdType="pmc">PMC3483417</ArticleId><ArticleId IdType="pubmed">23022481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Erauskin J, Tadokoro T, Baughn MW, Myers B, McAlonis-Downes M, Chillon-Marinas C, et al. ALS/FTD-linked mutation in FUS suppresses intra-axonal protein synthesis and drives disease without nuclear loss-of-function of FUS. Neuron. 2018;100:816&#x2013;30. doi: 10.1016/j.neuron.2018.09.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.044</ArticleId><ArticleId IdType="pmc">PMC6277851</ArticleId><ArticleId IdType="pubmed">30344044</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas-Jinu S, Gordon PM, Fielding T, Taylor R, Smith BN, Snowden V, et al. Non-nuclear pool of splicing factor SFPQ regulates axonal transcripts required for normal motor development. Neuron. 2017;94:931. doi: 10.1016/j.neuron.2017.04.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.036</ArticleId><ArticleId IdType="pmc">PMC5441113</ArticleId><ArticleId IdType="pubmed">28521142</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosker KE, Fenstermacher SJ, Pazyra-Murphy MF, Elliott HL, Segal RA. The RNA-binding protein SFPQ orchestrates an RNA regulon to promote axon viability. Nat Neurosci. 2016;19:690&#x2013;6.. doi: 10.1038/nn.4280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4280</ArticleId><ArticleId IdType="pmc">PMC5505173</ArticleId><ArticleId IdType="pubmed">27019013</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi A, Iida K, Tsubota T, Hosokawa M, Denawa M, Brown JB, et al. Loss of Sfpq causes long-gene transcriptopathy in the brain. Cell Rep. 2018;23:1326&#x2013;41.. doi: 10.1016/j.celrep.2018.03.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.03.141</ArticleId><ArticleId IdType="pubmed">29719248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo PK, Kar AN, Samra N, Terenzio M, Patel P, Lee SJ, et al. A Ca(2+)-dependent switch activates axonal casein kinase 2alpha translation and drives G3BP1 granule disassembly for axon regeneration. Curr Biol. 2020;30:4882&#x2013;95. doi: 10.1016/j.cub.2020.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2020.09.043</ArticleId><ArticleId IdType="pmc">PMC8182743</ArticleId><ArticleId IdType="pubmed">33065005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla Costa I, Buchanan CN, Zdradzinski MD, Sahoo PK, Smith TP, Thames E, et al. The functional organization of axonal mRNA transport and translation. Nat Rev Neurosci. 2021;22:77&#x2013;91. doi: 10.1038/s41583-020-00407-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-020-00407-7</ArticleId><ArticleId IdType="pmc">PMC8161363</ArticleId><ArticleId IdType="pubmed">33288912</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S, Holzbaur EL. Compartment-specific regulation of autophagy in primary neurons. J Neurosci. 2016;36:5933&#x2013;45. doi: 10.1523/JNEUROSCI.4401-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4401-15.2016</ArticleId><ArticleId IdType="pmc">PMC4887563</ArticleId><ArticleId IdType="pubmed">27251616</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;64. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Pal A, Goswami A, Lojewski X, Japtok J, Vehlow A, et al. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat Commun. 2018;9:335. doi: 10.1038/s41467-017-02299-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02299-1</ArticleId><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa S, Oikawa D, Ishii R, Ayaki T, Takahashi H, Takeda H, et al. Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis. Nat Commun. 2016;7:12547. doi: 10.1038/ncomms12547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12547</ArticleId><ArticleId IdType="pmc">PMC4999505</ArticleId><ArticleId IdType="pubmed">27552911</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Xie X, Wang Y, Liu J, Cheng X, Guo Y, et al. Structural insights into the interaction and disease mechanism of neurodegenerative disease-associated optineurin and TBK1 proteins. Nat Commun. 2016;7:12708. doi: 10.1038/ncomms12708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12708</ArticleId><ArticleId IdType="pmc">PMC5027247</ArticleId><ArticleId IdType="pubmed">27620379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Sellier C, Campanari ML, Charlet-Berguerand N, Kabashi E. The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway. Autophagy. 2016;12:1406&#x2013;8. doi: 10.1080/15548627.2016.1189070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1189070</ArticleId><ArticleId IdType="pmc">PMC4968221</ArticleId><ArticleId IdType="pubmed">27245636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Fujita K, Nakamura M, Wate R, Kaneko S, Sasaki S, et al. Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathol. 2011;121:555&#x2013;7. doi: 10.1007/s00401-011-0809-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0809-z</ArticleId><ArticleId IdType="pubmed">21327942</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015;130:77&#x2013;92. doi: 10.1007/s00401-015-1436-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1436-x</ArticleId><ArticleId IdType="pmc">PMC4470809</ArticleId><ArticleId IdType="pubmed">25943890</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyamin B, He J, Zhao Q, Gratten J, Garton F, Leo PJ, et al. Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. Nat Commun. 2017;8:611. doi: 10.1038/s41467-017-00471-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00471-1</ArticleId><ArticleId IdType="pmc">PMC5606989</ArticleId><ArticleId IdType="pubmed">28931804</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Nicholson AM, Sarkar M, Messing J, Purice MD, Pottier C, et al. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95:808&#x2013;16.. doi: 10.1016/j.neuron.2017.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan AL, Don EK, Rayner SL, Lee A, Laird AS, Watchon M, et al. Expression of ALS/FTD-linked mutant CCNF in zebrafish leads to increased cell death in the spinal cord and an aberrant motor phenotype. Hum Mol Genet. 2017;26:2616&#x2013;26.. doi: 10.1093/hmg/ddx136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx136</ArticleId><ArticleId IdType="pubmed">28444311</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Topp S, Yang S, Smith B, Fifita JA, Warraich ST, et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun. 2016;7:11253. doi: 10.1038/ncomms11253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11253</ArticleId><ArticleId IdType="pmc">PMC4835537</ArticleId><ArticleId IdType="pubmed">27080313</ArticleId></ArticleIdList></Reference><Reference><Citation>Edens BM, Yan J, Miller N, Deng HX, Siddique T, Ma YC. A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis. Elife. 2017;6:e25453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451210</ArticleId><ArticleId IdType="pubmed">28463112</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice JR, Gregory-Evans CY, Shaw CA. Modeling environmentally-induced motor neuron degeneration in zebrafish. Sci Rep. 2018;8:4890. doi: 10.1038/s41598-018-23018-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23018-w</ArticleId><ArticleId IdType="pmc">PMC5861069</ArticleId><ArticleId IdType="pubmed">29559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain KA, Sheng ZH. Mechanisms for the maintenance and regulation of axonal energy supply. J Neurosci Res. 2019;97:897&#x2013;913. doi: 10.1002/jnr.24411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24411</ArticleId><ArticleId IdType="pmc">PMC6565461</ArticleId><ArticleId IdType="pubmed">30883896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang CL, Rodenkirch L, Schultz JR, Chiu SY. A novel method to study the local mitochondrial fusion in myelinated axons in vivo. J Neurosci Methods. 2012;207:51&#x2013;8. doi: 10.1016/j.jneumeth.2012.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2012.03.013</ArticleId><ArticleId IdType="pmc">PMC3364104</ArticleId><ArticleId IdType="pubmed">22484559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Yu P, Lin MY, Sun T, Chen Y, Sheng ZH. Facilitation of axon regeneration by enhancing mitochondrial transport and rescuing energy deficits. J Cell Biol. 2016;214:103&#x2013;19. doi: 10.1083/jcb.201605101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201605101</ArticleId><ArticleId IdType="pmc">PMC4932375</ArticleId><ArticleId IdType="pubmed">27268498</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo K, Lim SM, Nahm M, Kim YE, Oh KW, Park HT, et al. A de novo RAPGEF2 variant identified in a sporadic amyotrophic lateral sclerosis patient impairs microtubule stability and axonal mitochondria distribution. Exp Neurobiol. 2018;27:550&#x2013;63.. doi: 10.5607/en.2018.27.6.550.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2018.27.6.550</ArticleId><ArticleId IdType="pmc">PMC6318558</ArticleId><ArticleId IdType="pubmed">30636905</ArticleId></ArticleIdList></Reference><Reference><Citation>Moller A, Bauer CS, Cohen RN, Webster CP, De Vos KJ. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum Mol Genet. 2017;26:4668&#x2013;79.. doi: 10.1093/hmg/ddx348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx348</ArticleId><ArticleId IdType="pmc">PMC5886184</ArticleId><ArticleId IdType="pubmed">28973175</ArticleId></ArticleIdList></Reference><Reference><Citation>Denton K, Mou Y, Xu CC, Shah D, Chang J, Blackstone C, et al. Impaired mitochondrial dynamics underlie axonal defects in hereditary spastic paraplegias. Hum Mol Genet. 2018;27:2517&#x2013;30.. doi: 10.1093/hmg/ddy156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy156</ArticleId><ArticleId IdType="pmc">PMC6031053</ArticleId><ArticleId IdType="pubmed">29726929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MY, Cheng XT, Xie Y, Cai Q, Sheng ZH. Removing dysfunctional mitochondria from axons independent of mitophagy under pathophysiological conditions. Autophagy. 2017;13:1792&#x2013;4.. doi: 10.1080/15548627.2017.1356552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2017.1356552</ArticleId><ArticleId IdType="pmc">PMC5640196</ArticleId><ArticleId IdType="pubmed">28812939</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Marissal N, Medard JJ, Azzedine H, Chrast R. Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration. Brain. 2015;138:875&#x2013;90. doi: 10.1093/brain/awv008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv008</ArticleId><ArticleId IdType="pubmed">25678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Ilieva H, Tamada H, Nomura H, Komine O, Endo F, et al. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. EMBO Mol Med. 2016;8:1421&#x2013;37.. doi: 10.15252/emmm.201606403.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606403</ArticleId><ArticleId IdType="pmc">PMC5167132</ArticleId><ArticleId IdType="pubmed">27821430</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaweda-Walerych K, Sitek EJ, Narozanska E, Buratti E. Parkin beyond Parkinson&#x2019;s disease-A functional meaning of Parkin downregulation in TDP-43 proteinopathies. Cells. 2021;10:3389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8699658</ArticleId><ArticleId IdType="pubmed">34943897</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo GM, Granatiero V, Kawamata H, Konrad C, Kim M, Arreguin AJ, et al. Parkin is a disease modifier in the mutant SOD1 mouse model of ALS. EMBO Mol Med. 2018;10:e8888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6180298</ArticleId><ArticleId IdType="pubmed">30126943</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14:459&#x2013;68.. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15:1488&#x2013;97. doi: 10.1038/nn.3230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3230</ArticleId><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Deng J, Wang P, Yang M, Chen X, Zhu L, et al. PINK1 and Parkin are genetic modifiers for FUS-induced neurodegeneration. Hum Mol Genet. 2016;25:5059&#x2013;68..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078632</ArticleId><ArticleId IdType="pubmed">27794540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol. 2021;141:257&#x2013;79.. doi: 10.1007/s00401-020-02252-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02252-5</ArticleId><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Zhou B, Lin MY, Wang S, Foust KD, Sheng ZH. Endolysosomal deficits augment mitochondria pathology in spinal motor neurons of asymptomatic fALS mice. Neuron. 2015;87:355&#x2013;70. doi: 10.1016/j.neuron.2015.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.06.026</ArticleId><ArticleId IdType="pmc">PMC4511489</ArticleId><ArticleId IdType="pubmed">26182418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono Y, Tanaka H, Takata M, Nagahara Y, Noda Y, Tsuruma K, et al. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neurosci Lett. 2014;559:174&#x2013;8. doi: 10.1016/j.neulet.2013.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.12.005</ArticleId><ArticleId IdType="pubmed">24334165</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. 2017;14:762&#x2013;72.. doi: 10.1007/s13311-016-0508-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuhashi T, Sato T, Kanno SI, Suzuki T, Matsuo A, Oba Y, et al. Mitochonic acid 5 (MA-5) facilitates ATP synthase oligomerization and cell survival in various mitochondrial diseases. EBioMedicine. 2017;20:27&#x2013;38. doi: 10.1016/j.ebiom.2017.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2017.05.016</ArticleId><ArticleId IdType="pmc">PMC5478234</ArticleId><ArticleId IdType="pubmed">28579242</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol Dis. 2017;105:283&#x2013;99.. doi: 10.1016/j.nbd.2017.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.02.004</ArticleId><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada Y, Yamazaki H, Sekine-Aizawa Y, Hirokawa N. The neuron-specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. Cell. 1995;81:769&#x2013;80. doi: 10.1016/0092-8674(95)90538-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90538-3</ArticleId><ArticleId IdType="pubmed">7539720</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouleau GA, Clark AW, Rooke K, Pramatarova A, Krizus A, Suchowersky O, et al. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:128&#x2013;31. doi: 10.1002/ana.410390119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390119</ArticleId><ArticleId IdType="pubmed">8572658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A, Donnenfeld H, Sasaki S, Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1984;43:461&#x2013;70. doi: 10.1097/00005072-198409000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198409000-00001</ArticleId><ArticleId IdType="pubmed">6540799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A, Nakano I, Kurland LT, Mulder DW, Holley PW, Saccomanno G. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1984;43:471&#x2013;80. doi: 10.1097/00005072-198409000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198409000-00002</ArticleId><ArticleId IdType="pubmed">6540800</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Yagishita S, Amano N, Yamaoka K, Kamei T. Amyotrophic lateral sclerosis with numerous axonal spheroids in the corticospinal tract and massive degeneration of the cortex. Acta Neuropathol. 1997;94:294&#x2013;9. doi: 10.1007/s004010050707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050707</ArticleId><ArticleId IdType="pubmed">9292701</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet. 2007;16:2720&#x2013;8.. doi: 10.1093/hmg/ddm226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm226</ArticleId><ArticleId IdType="pmc">PMC4516806</ArticleId><ArticleId IdType="pubmed">17725983</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci. 1999;2:50&#x2013;6. doi: 10.1038/4553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4553</ArticleId><ArticleId IdType="pubmed">10195180</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Cortez C, Gan WB, Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet. 2014;23:1413&#x2013;24. doi: 10.1093/hmg/ddt528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt528</ArticleId><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs KL, Kalmar B, Rhymes ER, Fellows AD, Ahmed M, Whiting P, et al. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596. doi: 10.1038/s41419-018-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0624-8</ArticleId><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SSW, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;43.. doi: 10.1016/j.neuron.2013.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R, et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan JE, Goldstein LS. The genetics of axonal transport and axonal transport disorders. PLoS Genet. 2006;2:e124. doi: 10.1371/journal.pgen.0020124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.0020124</ArticleId><ArticleId IdType="pmc">PMC1584265</ArticleId><ArticleId IdType="pubmed">17009871</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33:455&#x2013;6. doi: 10.1038/ng1123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1123</ArticleId><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004;63:724&#x2013;6. doi: 10.1212/01.WNL.0000134608.83927.B1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000134608.83927.B1</ArticleId><ArticleId IdType="pubmed">15326253</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Guo C, Hou G, Zhang H, Lu X, Williams JC, et al. Atomic-resolution structure of the CAP-Gly domain of dynactin on polymeric microtubules determined by magic angle spinning NMR spectroscopy. Proc Natl Acad Sci USA. 2015;112:14611&#x2013;6. doi: 10.1073/pnas.1509852112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509852112</ArticleId><ArticleId IdType="pmc">PMC4664305</ArticleId><ArticleId IdType="pubmed">26604305</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Noda Y, Tanaka Y, Niwa S. Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol. 2009;10:682&#x2013;96. doi: 10.1038/nrm2774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2774</ArticleId><ArticleId IdType="pubmed">19773780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fichera M, Lo Giudice M, Falco M, Sturnio M, Amata S, Calabrese O, et al. Evidence of kinesin heavy chain (KIF5A) involvement in pure hereditary spastic paraplegia. Neurology. 2004;63:1108&#x2013;10. doi: 10.1212/01.WNL.0000138731.60693.D2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000138731.60693.D2</ArticleId><ArticleId IdType="pubmed">15452312</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268&#x2013;83.e6. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Yilmaz R, Muller K, Grehl T, Petri S, Meyer T, et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018;141:688&#x2013;97.. doi: 10.1093/brain/awx370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx370</ArticleId><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbing B, Mann K, Starosta A, Jaud J, Schols L, Schule R, et al. Effect of spastic paraplegia mutations in KIF5A kinesin on transport activity. Hum Mol Genet. 2008;17:1245&#x2013;52.. doi: 10.1093/hmg/ddn014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn014</ArticleId><ArticleId IdType="pubmed">18203753</ArticleId></ArticleIdList></Reference><Reference><Citation>Citterio A, Arnoldi A, Panzeri E, Merlini L, D&#x2019;Angelo MG, Musumeci O, et al. Variants in KIF1A gene in dominant and sporadic forms of hereditary spastic paraparesis. J Neurol. 2015;262:2684&#x2013;90. doi: 10.1007/s00415-015-7899-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7899-9</ArticleId><ArticleId IdType="pubmed">26410750</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Katsuno M, Kawai K, Ishigaki S, Tanaka F, Sobue G. Disruption of axonal transport in motor neuron diseases. Int J Mol Sci. 2012;13:1225&#x2013;38. doi: 10.3390/ijms13011225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms13011225</ArticleId><ArticleId IdType="pmc">PMC3269748</ArticleId><ArticleId IdType="pubmed">22312314</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Tohnai G, Atsuta N, Nakatochi M, Hayashi N, Watanabe H, et al. Genetic and functional analysis of KIF5A variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2021;97:147. e11&#x2013;47 e17. doi: 10.1016/j.neurobiolaging.2020.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.07.010</ArticleId><ArticleId IdType="pubmed">32888732</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao YC, Fernandopulle MS, Wang G, Choi H, Hao L, Drerup CM, et al. RNA granules hitchhike on lysosomes for long-distance transport, using annexin A11 as a molecular tether. Cell. 2019;179:147&#x2013;64. doi: 10.1016/j.cell.2019.08.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.08.050</ArticleId><ArticleId IdType="pmc">PMC6890474</ArticleId><ArticleId IdType="pubmed">31539493</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Topp SD, Fallini C, Shibata H, Chen HJ, Troakes C, et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaad9157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cioni JM, Lin JQ, Holtermann AV, Koppers M, Jakobs MAH, Azizi A, et al. Late endosomes act as mRNA translation platforms and sustain mitochondria in axons. Cell. 2019;176:56&#x2013;72.e15. doi: 10.1016/j.cell.2018.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.11.030</ArticleId><ArticleId IdType="pmc">PMC6333918</ArticleId><ArticleId IdType="pubmed">30612743</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci. 2013;14:161&#x2013;76. doi: 10.1038/nrn3380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3380</ArticleId><ArticleId IdType="pubmed">23361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499&#x2013;503. doi: 10.1038/nature11280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11280</ArticleId><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A, et al. Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet. 2017;26:686&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968635</ArticleId><ArticleId IdType="pubmed">28040732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivadasan R, Hornburg D, Drepper C, Frank N, Jablonka S, Hansel A, et al. C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. Nat Neurosci. 2016;19:1610&#x2013;18.. doi: 10.1038/nn.4407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4407</ArticleId><ArticleId IdType="pubmed">27723745</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradi M, Sivadasan R, Saal L, Luningschror P, Dombert B, Rathod RJ, et al. Differential roles of alpha-, beta-, and gamma-actin in axon growth and collateral branch formation in motoneurons. J Cell Biol. 2017;216:793&#x2013;814. doi: 10.1083/jcb.201604117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201604117</ArticleId><ArticleId IdType="pmc">PMC5346967</ArticleId><ArticleId IdType="pubmed">28246119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron C, Beric-Maskarel K, Muntasser S, Weyer L, Somerville MJ, Percy ME. Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons. J Neuropathol Exp Neurol. 1994;53:221&#x2013;30.. doi: 10.1097/00005072-199405000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199405000-00002</ArticleId><ArticleId IdType="pubmed">7909836</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbo M, Hays AP. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol. 1992;51:531&#x2013;7. doi: 10.1097/00005072-199209000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199209000-00008</ArticleId><ArticleId IdType="pubmed">1381416</ArticleId></ArticleIdList></Reference><Reference><Citation>Freudiger CW, Min W, Saar BG, Lu S, Holtom GR, He C, et al. Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy. Science. 2008;322:1857&#x2013;61. doi: 10.1126/science.1165758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165758</ArticleId><ArticleId IdType="pmc">PMC3576036</ArticleId><ArticleId IdType="pubmed">19095943</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;90.. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon S, Gupton S. Recent advances in branching mechanisms underlying neuronal morphogenesis. F1000Res. 2018;7:F1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234733</ArticleId><ArticleId IdType="pubmed">30473771</ArticleId></ArticleIdList></Reference><Reference><Citation>Osking Z, Ayers JI, Hildebrandt R, Skruber K, Brown H, Ryu D, et al. ALS-linked SOD1 mutants enhance neurite outgrowth and branching in adult motor neurons. iScience. 2019;11:294&#x2013;304. doi: 10.1016/j.isci.2018.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2018.12.026</ArticleId><ArticleId IdType="pmc">PMC6327879</ArticleId><ArticleId IdType="pubmed">30639851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2010;19:671&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird AS, Van Hoecke A, De Muynck L, Timmers M, Van den Bosch L, Van Damme P, et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE. 2010;5:e13368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954192</ArticleId><ArticleId IdType="pubmed">20967127</ArticleId></ArticleIdList></Reference><Reference><Citation>Garone MG, Birsa N, Rosito M, Salaris F, Mochi M, de Turris V, et al. ALS-related FUS mutations alter axon growth in motoneurons and affect HuD/ELAVL4 and FMRP activity. Commun Biol. 2021;4:1025. doi: 10.1038/s42003-021-02538-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02538-8</ArticleId><ArticleId IdType="pmc">PMC8410767</ArticleId><ArticleId IdType="pubmed">34471224</ArticleId></ArticleIdList></Reference><Reference><Citation>McWhorter ML, Monani UR, Burghes AH, Beattie CE. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol. 2003;162:919&#x2013;31. doi: 10.1083/jcb.200303168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200303168</ArticleId><ArticleId IdType="pmc">PMC1761110</ArticleId><ArticleId IdType="pubmed">12952942</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, De Luca A, Hogan AL, Rayner SL, Davidson JM, Watchon M, et al. Unbiased label-free quantitative proteomics of cells expressing amyotrophic lateral sclerosis (ALS) mutations in CCNF reveals activation of the apoptosis pathway: a workflow to screen pathogenic gene mutations. Front Mol Neurosci. 2021;14:627740. doi: 10.3389/fnmol.2021.627740.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.627740</ArticleId><ArticleId IdType="pmc">PMC8111008</ArticleId><ArticleId IdType="pubmed">33986643</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Yoon BC, Holt CE. Axonal mRNA localization and local protein synthesis in nervous system assembly, maintenance and repair. Nat Rev Neurosci. 2012;13:308&#x2013;24. doi: 10.1038/nrn3210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3210</ArticleId><ArticleId IdType="pmc">PMC3682205</ArticleId><ArticleId IdType="pubmed">22498899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;38. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP. Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron. 2017;96:285&#x2013;97.. doi: 10.1016/j.neuron.2017.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.029</ArticleId><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, Taylor JP. Bridging biophysics and neurology: aberrant phase transitions in neurodegenerative disease. Nat Rev Neurol. 2019;15:272&#x2013;86.. doi: 10.1038/s41582-019-0157-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0157-5</ArticleId><ArticleId IdType="pubmed">30890779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Ivanov P, Anderson P. Stress granules and cell signaling: more than just a passing phase? Trends Biochem Sci. 2013;38:494&#x2013;506. doi: 10.1016/j.tibs.2013.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2013.07.004</ArticleId><ArticleId IdType="pmc">PMC3832949</ArticleId><ArticleId IdType="pubmed">24029419</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogaert E, Boeynaems S, Kato M, Guo L, Caulfield TR, Steyaert J, et al. Molecular dissection of FUS points at synergistic effect of low-complexity domains in toxicity. Cell Rep. 2018;24:529&#x2013;37. doi: 10.1016/j.celrep.2018.06.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.06.070</ArticleId><ArticleId IdType="pmc">PMC6077250</ArticleId><ArticleId IdType="pubmed">30021151</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT, Kato M, Lin Y, Thurber KR, Hung I, McKnight SL, et al. Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. Cell. 2017;171:615&#x2013;27. doi: 10.1016/j.cell.2017.08.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.08.048</ArticleId><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoads SN, Monahan ZT, Yee DS, Leung AY, Newcombe CG, O&#x2019;Meally RN, et al. The prionlike domain of FUS is multiphosphorylated following DNA damage without altering nuclear localization. Mol Biol Cell. 2018;29:1786&#x2013;97.. doi: 10.1091/mbc.E17-12-0735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E17-12-0735</ArticleId><ArticleId IdType="pmc">PMC6085830</ArticleId><ArticleId IdType="pubmed">29897835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicardi ME, Marrone L, Azzouz M, Trotti D. Proteostatic imbalance and protein spreading in amyotrophic lateral sclerosis. EMBO J. 2021;40:e106389. doi: 10.15252/embj.2020106389.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106389</ArticleId><ArticleId IdType="pmc">PMC8126909</ArticleId><ArticleId IdType="pubmed">33792056</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;92. doi: 10.1016/j.cell.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, Ali R, Jiou J, Fung HYJ, Burke KA, Kim SJ, et al. Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites. Cell. 2018;173:693&#x2013;705.e22. doi: 10.1016/j.cell.2018.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.003</ArticleId><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, Hutten S, Bourgeois B, Spreitzer E, Niedner-Boblenz A, Schifferer M, et al. Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell. 2018;173:706&#x2013;19. doi: 10.1016/j.cell.2018.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.004</ArticleId><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S, Wang G, Randle SJ, Ruggeri FS, Varela JA, Lin JQ, et al. FUS phase separation is modulated by a molecular chaperone and methylation of arginine cation-pi interactions. Cell. 2018;173:720&#x2013;34. doi: 10.1016/j.cell.2018.03.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.056</ArticleId><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwon Y, Maxwell BA, Kolaitis RM, Zhang P, Kim HJ, Taylor JP. Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner. Science. 2021;372:eabf6548. doi: 10.1126/science.abf6548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6548</ArticleId><ArticleId IdType="pmc">PMC8574224</ArticleId><ArticleId IdType="pubmed">34739333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler JR, Matheny T, Jain S, Abrisch R, Parker R. Distinct stages in stress granule assembly and disassembly. Elife. 2016;5:e18413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014549</ArticleId><ArticleId IdType="pubmed">27602576</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Lu S, Gasior K, Singh D, Vazquez-Sanchez S, Tapia O, et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371:eabb4309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, et al. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173:958&#x2013;71. doi: 10.1016/j.cell.2018.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanneste J, Van Den Bosch L. The role of nucleocytoplasmic transport defects in amyotrophic lateral sclerosis. Int J Mol Sci. 2021;22:12175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620263</ArticleId><ArticleId IdType="pubmed">34830069</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, Khalil B, Smith CL, Rossoll W. Traffic jam at the nuclear pore: all roads lead to nucleocytoplasmic transport defects in ALS/FTD. Neurobiol Dis. 2020;140:104835. doi: 10.1016/j.nbd.2020.104835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104835</ArticleId><ArticleId IdType="pmc">PMC7253339</ArticleId><ArticleId IdType="pubmed">32179176</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Gorlich D. Transport selectivity of nuclear pores, phase separation, and membraneless organelles. Trends Biochem Sci. 2016;41:46&#x2013;61. doi: 10.1016/j.tibs.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2015.11.001</ArticleId><ArticleId IdType="pubmed">26705895</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster BM, Colombi P, Jager J, Lusk CP. Surveillance of nuclear pore complex assembly by ESCRT-III/Vps4. Cell. 2014;159:388&#x2013;401. doi: 10.1016/j.cell.2014.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.09.012</ArticleId><ArticleId IdType="pmc">PMC4194032</ArticleId><ArticleId IdType="pubmed">25303532</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Baskerville V, Zaepfel BL, Dickson DW, Rigo F, Bennett F, et al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci Transl Med. 2021;13:eabe1923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022198</ArticleId><ArticleId IdType="pubmed">34321318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Kumar MS, Ramesh N, Anderson EN, Nguyen AT, Kim B, et al. Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway. Nat Neurosci. 2021;24:1077&#x2013;88.. doi: 10.1038/s41593-021-00859-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00859-9</ArticleId><ArticleId IdType="pmc">PMC8832378</ArticleId><ArticleId IdType="pubmed">34059832</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanaura H, Kawamukai H, Fujiwara A, Uehara T, Aiba Y, Nakanishi M, et al. C9orf72-derived arginine-rich poly-dipeptides impede phase modifiers. Nat Commun. 2021;12:5301. doi: 10.1038/s41467-021-25560-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25560-0</ArticleId><ArticleId IdType="pmc">PMC8421406</ArticleId><ArticleId IdType="pubmed">34489423</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The &#x201c;Dying-Back&#x201d; phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43:470&#x2013;7. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker MR. ALS-dying forward, backward or outward? Nat Rev Neurol. 2014;10:660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4221249</ArticleId><ArticleId IdType="pubmed">25245152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M, Brown RH, Jr. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2018;8:a024125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>